{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-017671","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2023-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.147163+00:00","generated_at":"2026-06-17T03:55:13.264115+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Eterna Therapeutics secures up to $10M equity line from Lincoln Park Capital","bullets":["Lincoln Park committed to buy up to $10M of common stock over 24 months at Company's discretion.","Company issued 73,659 shares as commitment fee; purchases subject to volume and price limits.","No upper limit on purchase price per share; Lincoln Park cannot short or hedge during term.","Sales limited to 19.99% of outstanding shares unless stock price exceeds $3.6094 or shareholder approval obtained.","Company may terminate agreement with one business day notice; no penalties or liquidated damages."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-017671","json":"https://secwatch.observer/filing/0001140361-23-017671.json","markdown":"https://secwatch.observer/filing/0001140361-23-017671.md","text":"https://secwatch.observer/filing/0001140361-23-017671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036123017671/0001140361-23-017671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036123017671/brhc10050812_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:55:13.264115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97d3dddffe0b48cd9574afde4f71df76cdb48cb4","claim":"Ernexa Therapeutics Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $10.0 million (effective 2023-04-05).","evidence_excerpt":"On April 5, 2023, Eterna Therapeutics Inc., a Delaware corporation (the \" Company \"), entered into a purchase agreement (the \" Purchase Agreement \") and a registration rights agreement (the \" Registration Rights Agreement \") with Lincoln Park Capital Fund, LLC (\" Lincoln Park \"), pursuant to which Lincoln Park has committed to purchase up to $10.0 million of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123017671/0001140361-23-017671-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Lincoln Park Capital Fund, LLC"},{"label":"Value","value":"up to $10.0 million"},{"label":"Effective","value":"2023-04-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}